Manila Times Business
Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
Distinguished panel of experts in psychiatry and neuroscience appointed to guide Phase 3 confirmatory trial of roluperidone and broader R&D strategy BURLINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the formation of its Scientific Advisory Board (SAB), fulfilling a commitment made in connection with the Compan
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Guggenheim Investments Announces June 2026 Closed-End Fund Distributions
1h ago
University of Miami Miller School of Medicine Names Dr. Pradeep Ramulu Chair of Ophthalmology and the Bascom Palmer Eye Institute
1h ago
Xometry Announces Proposed Public Offering of Class A Common Stock
1h ago
Hallador Energy Acquires 460 MW of Siemens Turbines for $350 Million, Accelerating Merom Natural Gas Generation Project
1h ago